• 4 min read
• Published on 7 November 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 7 November 2026
Read article
The Coverage Cliff. Major insurers are dropping corporate drug benefits, leaving millions stranded without coverage. The landmark Hims Hers Eli Lilly deal cuts out the insurer entirely, giving self-pay patients a direct path forward.
Bypassing the Middlemen. Pharma leaders are shifting toward direct-to-consumer pipelines rather than fighting benefit managers. Distributing Hims Hers Zepbound at clear cash prices lets drugmakers secure dependable demand from self-funded buyers.
Opening the Digital Door. Surging demand has put GLP-1 telehealth stocks at the heart of virtual medicine. With fractional shares and AI insights from a regulated broker, building a balanced healthcare portfolio doesn't require massive upfront capital.
The Out-of-Pocket Wall. Widening Hims Hers stock GLP-1 access may look bright, but treatments still cost hundreds of pounds each month. If consumer wallets pinch or regulations shift, high valuations could face sudden pressure.
Call me cynical, but whenever a healthcare behemoth preaches the gospel of patient wellness, I instinctively check my pocket for my wallet. Consider Cigna. The American insurance titan recently decided it could no longer stomach paying for blockbuster GLP-1 slimming jabs for its own staff.
When the people writing the policies pull the plug, where does that leave the patient?
At the digital checkout, credit card in hand.
Eli Lilly has struck an intriguing alliance with telehealth platform Hims & Hers to sell its prized Zepbound alongside a newer therapy, Foundayo, directly to consumers at self-pay prices. To me, this looks less like standard corporate cooperation and more like an aggressive end-run around an ossified medical system. If your employer refuses to rubber-stamp the prescription, you cut out the GP, skip the paperwork, and buy it online.
It solves an irritating dilemma for both parties. Lilly secures a direct pipeline to motivated consumers without losing market share to shadowy compounding pharmacies. Hims & Hers, meanwhile, earns the legitimacy of distributing branded medicine rather than quasi-legal alternatives.
This consumer rebellion sits right at the centre of The GLP-1 Insurance Gap Reshaping Weight Care in 2026, where virtual platforms could increasingly plug the holes left by retreating insurers.
Yet, before investors treat this pivot as an automatic licence to print money, we ought to inject a sensible dose of reality.
Self-pay economies rely entirely on affluent stamina.
Shelling out several hundred pounds every month for vanity or vitality is feasible during a boom, but personal balances are not bottomless. If economic belts tighten, costly recurring subscriptions are often the first domestic luxuries cast overboard.
Regulatory goalposts also have a nasty habit of moving without warning. Hims & Hers has endured sharp regulatory headaches over bespoke drug mixes, and its stock price remains notoriously volatile. Even an established titan like Eli Lilly faces potential political pushback over retail pricing and the looming reality of patent expiries.
This commercial shift may open an enormous private market, but it could just as easily suffer from high customer turnover and pricing friction. Investing here might offer compelling exposure to modern medical habits, but do not mistake a clever distribution deal for a risk-free ride.
View the full Basket:The GLP-1 Insurance Gap Reshaping Weight Care in 2026
View the full Basket:The GLP-1 Insurance Gap Reshaping Weight Care in 2026
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 7 November 2026
Read article